Search

Displaying results 5221 - 5230 of 8974 in total
  1. Drug

    Black widow spider antivenin (equine)

    go.drugbank.com/drugs/DB14113
    Approved

    Black widow spider (_Latrodectus mactans_) antivenin is a treatment for black widow spider bites derived from the serum of healthy horses immunized against black widow spider venom.[L12792]

  2. Drug

    Desoxyribonuclease

    go.drugbank.com/drugs/DB09551
    ApprovedInvestigational

    The enzyme's cofactor is reported to be magnesium (or manganese) ions, although the optimal concentration of the ion is independent of the enzyme concentration [A31251].

  3. Drug

    Etiracetam

    go.drugbank.com/drugs/DB11868
    Experimental

    Etiracetam is under investigation in clinical trial NCT01137110 (Comparison of Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After Subarachnoid Hemorrhage (SAH)).

  4. Drug

    GW-468816

    go.drugbank.com/drugs/DB15099
    Experimental

    GW-468816 is under investigation in clinical trial NCT00218465 (Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking).

  5. Drug

    Maropitant

    go.drugbank.com/drugs/DB11427
    ExperimentalVet approved

    It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats. … Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs.

  6. Drug

    Zalutumumab

    go.drugbank.com/drugs/DB12202
    Investigational

    Zalutumumab has been investigated for the treatment of Squamous Cell Cancer and Head and Neck Cancer. … Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR).

  7. Target

    Serine/threonine-protein kinase SIK1

    go.drugbank.com/bio_entities/BE0004757
    TargetHumans

    Acts as a tumor suppressor and plays a key role in p53/TP53-dependent anoikis, a type of apoptosis triggered by cell detachment: required for phosphorylation of p53/TP53 in response to loss of adhesion … and is able to suppress metastasis.

    Synonyms: Salt-inducible kinase 1
  8. Drug

    Talnetant

    go.drugbank.com/drugs/DB06429
    Investigational

    Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential … antipsychotic drug for the treatment of schizophrenia.

  9. Drug

    AM336

    go.drugbank.com/drugs/DB06563
    Experimental

    Leconotide (development codes CNSB004 and AM336) is an omega-conotoxin peptide known for its analgesic properties, which work by blocking neuronal voltage-sensitive calcium channels. … It was investigated as a potential treatment for various pain conditions.

  10. Drug

    Alectinib

    go.drugbank.com/drugs/DB11363
    ApprovedInvestigational

    Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance